The chemical evolution of oligonucleotide therapies of clinical utility
Top Cited Papers
Open Access
- 27 February 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 35 (3), 238-248
- https://doi.org/10.1038/nbt.3765
Abstract
Refinements in the chemistries employed in oligonucleotide therapeutics have galvanized clinical progress. The complex interplay between chemical modifications and integration into sequence architecture is discussed in the context of antisense and small-interfering RNA drugs. After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful clinical productivity. One of the key advantages of oligonucleotide drugs is that their delivery and potency are derived primarily from the chemical structure of the oligonucleotide whereas their target is defined by the base sequence. Thus, as oligonucleotides with a particular chemical design show appropriate distribution and safety profiles for clinical gene silencing in a particular tissue, this will open the door to the rapid development of additional drugs targeting other disease-associated genes in the same tissue. To achieve clinical productivity, the chemical architecture of the oligonucleotide needs to be optimized with a combination of sugar, backbone, nucleobase, and 3′- and 5′-terminal modifications. A portfolio of chemistries can be used to confer drug-like properties onto the oligonucleotide as a whole, with minor chemical changes often translating into major improvements in clinical efficacy. One outstanding challenge in oligonucleotide chemical development is the optimization of chemical architectures to ensure long-term safety. There are multiple designs that enable effective targeting of the liver, but a second challenge is to develop architectures that enable robust clinical efficacy in additional tissues.Keywords
This publication has 134 references indexed in Scilit:
- The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencingThe EMBO Journal, 2013
- 5′ Unlocked Nucleic Acid Modification Improves siRNA TargetingMolecular Therapy Nucleic Acids, 2013
- Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin ExpressionCell, 2012
- RNA-Based Therapeutics: Current Progress and Future ProspectsCell Chemical Biology, 2012
- siRNA-optimized Modifications for Enhanced In Vivo ActivityMolecular Therapy Nucleic Acids, 2012
- Stability and Mismatch Discrimination of Locked Nucleic Acid–DNA DuplexesBiochemistry, 2011
- Unique Gene‐Silencing and Structural Properties of 2′‐Fluoro‐Modified siRNAsAngewandte Chemie-International Edition, 2011
- Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG RepeatBiochemistry, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi proteinNature, 2005